Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 9,936 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Interventions: asciminib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more

Conditions: Chronic Low Back Pain
Interventions: Web-module for patient education and planning; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriatic Arthritis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more

Conditions: Major Depression
Interventions: Psilocybin, modafinil, zolpidem, pimavanserin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 1 more

Conditions: Labor Pain
Interventions: 50% Nitrous Oxide/50% Oxygen; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Standard of Care Distressed in study Arm Distressed, Psycho-Education, Team Based Care, Standard of Care Non-Distressed; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Tobacco Dependence
Interventions: Varenicline, Nicotine patch, Placebo Patch, Placebo Pill; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Hemophilia A
Interventions: ASC618; Biological
Lead sponsor: ASC Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Presbyopia
Interventions: Clerio Vision LIRIC-modified Bifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, Clerio Vision Single Vision Contact Lens; Device
Lead sponsor: Clerio Vision, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension
Interventions: mHealth Coaching Intervention, Enhanced Usual Care; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Pregabalin, Placebo, Bowel preparation; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Asthma
Interventions: Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more

Conditions: Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Interventions: MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole; Drug
Lead sponsor: Metagen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Naples, Florida • Boston, Massachusetts • New York, New York

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Placebo, BIIB014 50mg, BIIB014 100mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Coronary Artery Disease, Heart Diseases
Interventions: Single arterial graft, Multiple arterial grafting; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 11
States / cities: Boulder, Colorado • Springfield, Massachusetts • Lincoln, Nebraska + 5 more

Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Migraine Disease, Patent Foramen Ovale
Interventions: Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: End Stage Renal Disease, Cardiovascular Disease, Inflammation
Interventions: Pomegranate juice, Pomegranate fruit extract; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Mantle Cell Lymphoma
Interventions: Rituximab, bortezomib, Cladribine; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Hershey, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions: Vyvanse (lisdexamfetamine dimesylate), NRP104; Drug
Lead sponsor: New River Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 45
States / cities: Little Rock, Arkansas • El Centro, California • Irvine, California + 40 more

Conditions: Healthy
Interventions: Choice of TIV or FluMist with baseline advertisement, Choice of TIV or FluMist with enhanced advertisement and incentives, Control - Usual care offering TIV only with baseline advertisement; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 4,411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 47
States / cities: Chatsworth, California • Novato, California • Sacramento, California + 34 more

Conditions: Absence; Kidney
Interventions: rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Search by objective public record fields.

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

MEPS-Pain: Personalized Pain Self-management Planning by and for Veterans Pilot Study

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psilocybin for Depression in Veterans

Comparing Sedara to Butorphanol in Early Labor

Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients

UW Quitting Using Intensive Treatment Study (QUITS)

ASC618 Gene Therapy in Hemophilia A Patients

Bifocal Contact Lens Study for Adults With Age-Related Near Vision Loss

Mobile Health Management of Hypertension

Pregabalin and Colonic Function

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

BIIB014 Cardiovascular Monitoring Study

Randomization of Single vs Multiple Arterial Grafts

Photopheresis in Early-stage Mycosis Fungoides

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

Pomegranate and Hemodialysis Pilot Trial

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Assessing Choice in the Employer Setting (ACES) Study

Sirolimus Conversions in African-American Renal Transplant Recipients

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms